Delivery Order SPE2DB20D2014-SPE2DB25FD03F
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,702.33 to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injectors. This firm fixed price, non-set-aside delivery order is scheduled for completion by July 24, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,573.99 for Zepbound 10 mg/0.5 mL pen injections on May 30, 2025, with completion targeted for June 2, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and identifies AmerisourceBergen's Conshohocken, Pennsylvania location as the place of performance. The delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency (DLA) awarded a $12,636.36 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 ml pen injections on August 29, 2025, with a completion date of September 2, 2025. This delivery order represents a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The award was competitively awarded with no set-aside designation and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,625.80 to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injectors. The contract represents a firm fixed price delivery order with an ultimate completion date of August 15, 2025, and was competitively awarded without set-aside provisions. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $2,287.74 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pen injections on August 29, 2025, with an ultimate completion date of September 2, 2025. This competitive, non-set-aside contract utilizes firm fixed pricing and is being fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,669.05 on August 18, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections. The contract employs firm fixed pricing with no set-aside designation, indicating competitive award, and specifies performance completion by August 19, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime...
- The Defense Logistics Agency has awarded a delivery order valued at $5,248.48 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pen injectors. This firm fixed-price delivery order, issued on September 5, 2025, with an ultimate completion date of September 8, 2025, represents a competitively awarded non-set-aside contract. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary distribution...
- The Defense Logistics Agency awarded a $16,403.16 delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injectors. This firm fixed price, non-competitive delivery order is set to be completed by August 29, 2025, with performance executed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support...
- AmerisourceBergen Drug Corp was awarded a $12,668.89 delivery order by the Defense Logistics Agency (DLA) on September 17, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections (0.5 mL). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of September 18, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under...
- The Defense Logistics Agency awarded a $30,324 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Zepbound 5 mg/0.5 ml pen injectors (0.5 ml). This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by September 17, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. As a critical pharmaceutical distributor supporting federal medical procurement,...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FD03FDelivery Order
The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $6,340.26 on September 17, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injections. The contract utilizes firm fixed-price pricing with no set-aside designation and is scheduled for completion by September 18, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999,999,999 ceiling and extends through December 2026, serving as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal vendor specializing in medical procurement for military and veteran healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to supply diverse pharmaceutical products, medical devices, and healthcare commodities across multiple therapeutic domains. This particular order for Zepbound, a GLP-1 receptor agonist medication, reflects the company's role in supporting the Defense Health Agency and broader military healthcare supply chain requirements. The award was made through open competition without set-aside provisions, consistent with AmerisourceBergen's track record of competitively winning federal contracts across various delivery orders with pricing ranging from nominal amounts to six-figure transactions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.3k | 9/17/25 |